Trial · NCT00148733
CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
NCT00148733, Phase 2, Phase 3, Completed, Centre For International Health; results first posted 2015-02-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia. Trials, record NCT00148733. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00148733
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
- NCT number
- NCT00148733
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 2,628 participants, actual
- Lead sponsor
- Centre For International Health
- Conditions
- Pneumonia
- Interventions
- Zinc
- First posted
- 2005-09-08
- Last updated
- 2022-03-16
- Results first posted
- 2015-02-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Risk of Treatment Failure. | Within 2 weeks after enrollment | Enrolled children will be followed and given zinc or placebo for 14 days. We will compare the proportion with treatment failure (i.e. lack of improvement within 3 days) between the two groups |
| Primary | Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been Initiated | Within 2 weeks after enrollment | We will measure to what extent the intervention can reduce the number of severe events. |
| Primary | Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is Completed | six months | We will measure to what extent short term zinc administration has an impact on growth and morbidity for up to 6 months after end of supplementation |
| Primary | Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc Supplementation | six months | Thymus size will be measured using ultrasonography and compared between the two groups. at two occasions 2.5 and 6 months after end of supplementation |
| Primary | Adverse Effects | 14 days | Vomiting, regurgitation, pain in abdomen for 15 minutes after zinc or placebo administration. |
| Secondary | Effect Modifiers for the Effect of Zinc Given During Pneumonia | Within 2 weeks after enrollment | We will also measure of there are factors at baseline that modifies the effect of zinc. Whether the following are modifiers for the above-mentioned effect of zinc given during pneumonia: i.severe inflammation, reflected in: high fever and/or elevated plasma C-reactive protein (CRP) concentration |
| Secondary | The Efficacy of Zinc According to Breast Feeding Status and in Different Age Categories | Within 2 weeks after enrollment | We will measure to what extent breastfeeding status modifies the effect of zinc on pneumonia |
| Secondary | The Efficacy of Zinc in Malnourished and Non-malnourished Children | Within 2 weeks after enrollment | We will compare the efficacy of zinc in those that are stunted, wasted or underweight with those who are not. |
| Secondary | Will Presence of a RNA Virus Modify the Effect of Zinc | 14 days | We will compare the efficacy of zinc according to virus detected in nasopharyngeal secretions |
| Secondary | Folate, Cobalamin and Vitamin D Status of the Enrolled Children | 14 days | And whether or not these vitamins predict treatment failure and duration of illness. |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Risk of Treatment Failure. | Within 2 weeks after enrollment | participants | NUMBER | |
| PRIMARY | Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been Initiated | Within 2 weeks after enrollment | |||
| PRIMARY | Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is Completed | six months | |||
| PRIMARY | Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc Supplementation | six months | |||
| PRIMARY | Adverse Effects | 14 days | |||
| SECONDARY | Effect Modifiers for the Effect of Zinc Given During Pneumonia | Within 2 weeks after enrollment | |||
| SECONDARY | The Efficacy of Zinc According to Breast Feeding Status and in Different Age Categories | Within 2 weeks after enrollment | |||
| SECONDARY | The Efficacy of Zinc in Malnourished and Non-malnourished Children | Within 2 weeks after enrollment | |||
| SECONDARY | Will Presence of a RNA Virus Modify the Effect of Zinc | 14 days | |||
| SECONDARY | Folate, Cobalamin and Vitamin D Status of the Enrolled Children | 14 days |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Risk of Treatment Failure. | Zinc | 267 | participants | ||
| Risk of Treatment Failure. | Placebo | 253 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Zinc | 1,314 | |
| Overall Study | STARTED | Placebo | 1,314 | |
| Overall Study | COMPLETED | Zinc | 1,300 | |
| Overall Study | COMPLETED | Placebo | 1,299 | |
| Overall Study | NOT COMPLETED | Zinc | 14 | |
| Overall Study | NOT COMPLETED | Placebo | 15 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Regurgitation | Gastrointestinal disorders | Zinc | 181 | 1,314 | |
| other | Regurgitation | Gastrointestinal disorders | Placebo | 53 | 1,314 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Zinc | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Zinc | 181 | 1,314 |
| Total, other adverse events | Placebo | 53 | 1,314 |
| Total, serious adverse events | Zinc | 0 | 1,314 |
| Total, serious adverse events | Placebo | 0 | 1,314 |
Source ClinicalTrials.gov
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Zinc vs Placebo: Risk of Treatment Failure. | Trial comparisons |
| Zinc vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00148733
GET https://conductscience.org/api/trials/v1/NCT00148733/papers?page=2